- Home
- PGRE vs NEO Comparison
PGRE vs NEO Comparison
Compare PGRE & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGRE
- NEO
- Stock Information
- Founded
- PGRE 1978
- NEO 2001
- Country
- PGRE United States
- NEO United States
- Employees
- PGRE N/A
- NEO N/A
- Industry
- PGRE Real Estate Investment Trusts
- NEO Precision Instruments
- Sector
- PGRE Real Estate
- NEO Health Care
- Exchange
- PGRE Nasdaq
- NEO Nasdaq
- Market Cap
- PGRE 1.4B
- NEO 1.1B
- IPO Year
- PGRE 2014
- NEO 1999
- Fundamental
- Price
- PGRE $6.53
- NEO $9.11
- Analyst Decision
- PGRE Hold
- NEO Buy
- Analyst Count
- PGRE 5
- NEO 10
- Target Price
- PGRE $6.15
- NEO $12.56
- AVG Volume (30 Days)
- PGRE 7.5M
- NEO 2.9M
- Earning Date
- PGRE 10-29-2025
- NEO 10-28-2025
- Dividend Yield
- PGRE N/A
- NEO N/A
- EPS Growth
- PGRE N/A
- NEO N/A
- EPS
- PGRE N/A
- NEO N/A
- Revenue
- PGRE $701,980,000.00
- NEO $689,189,000.00
- Revenue This Year
- PGRE $1.41
- NEO $10.40
- Revenue Next Year
- PGRE N/A
- NEO $10.11
- P/E Ratio
- PGRE N/A
- NEO N/A
- Revenue Growth
- PGRE 35.23
- NEO 9.70
- 52 Week Low
- PGRE $3.75
- NEO $4.72
- 52 Week High
- PGRE $7.85
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- PGRE 40.67
- NEO 67.10
- Support Level
- PGRE $6.51
- NEO $7.56
- Resistance Level
- PGRE $6.56
- NEO $8.01
- Average True Range (ATR)
- PGRE 0.03
- NEO 0.38
- MACD
- PGRE -0.02
- NEO 0.06
- Stochastic Oscillator
- PGRE 22.22
- NEO 92.86
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. The company derives nearly all of its majority of revenue from rental income.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.